Tailoring Hormone Therapy for Prostate Cancer with Genetic Subtyping

Trial Analysis Evaluates Genetic Testing for Post-Surgery Treatment

Tailoring hormone therapy for prostate cancer after surgery may depend on identifying specific tumor biology before adding medication. A secondary analysis of the NRG-RTOG 0534 SPPORT trial evaluated whether the PAM50 genomic classifier could identify patients who benefit from hormone suppression. Researchers presented the data at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting and published findings in the International Journal of Radiation Oncology Biology Physics.

The investigation analyzed prostate tissue from 709 men who had a detectable or rising prostate-specific antigen (PSA) level after a prostatectomy. In the original trial, participants received salvage radiation to the prostate bed alone, radiation with short-term androgen deprivation therapy (STADT), or radiation with STADT and pelvic lymph-node radiation. The new analysis examined whether tumors classified as Luminal B (LumB) responded differently to the addition of hormone therapy than non-LumB tumors.

Luminal B prostate tumors display increased androgen receptor signaling and typically present a higher risk of disease progression. Lead investigator Phuoc T. Tran, M.D., Ph.D., from the University of Texas MD Anderson Cancer Center, evaluated whether this biology made LumB tumors especially sensitive to testosterone suppression.

Absolute Survival Differences Between Molecular Subtypes

Adding short-term androgen deprivation therapy provided substantially higher risk reductions for patients with Luminal B tumors than for patients with non-LumB tumors. Men with LumB tumors experienced a 31% absolute improvement in freedom from progression at five years when receiving hormone therapy compared to radiation alone. Patients with non-LumB tumors achieved an absolute improvement of 10% across the same timeframe, establishing a statistically significant interaction (p=0.01).

The divergence persisted across ten years of follow-up for distant disease spread. Men carrying LumB tumors saw a 20% absolute improvement in metastasis-free survival when clinicians added hormone therapy to salvage radiation. In contrast, men with non-LumB tumors saw a -3% difference, indicating no measurable metastasis reduction from the drug intervention (p=0.05).

• Five-year freedom from progression improved by 31% in Luminal B cases compared to 10% in non-Luminal B cases.
• Ten-year metastasis-free survival improved by 20% in Luminal B cases compared to -3% in non-Luminal B cases.
• Tissue analysis was completed across 709 patient samples from the SPPORT trial cohort.

Metabolic Considerations Surrounding Androgen Suppression

Hormone therapy for prostate cancer relies on androgen deprivation, which carries documented systemic metabolic effects. Suppressing circulating testosterone alters body composition by reducing lean skeletal muscle mass and increasing central adiposity. These shifts often impair resting insulin sensitivity and elevate baseline cardiovascular risk markers during the active treatment window.

Understanding which patients derive true survival advantages from hormone suppression helps balance these systemic metabolic consequences. When therapy yields minimal metastasis reduction, patients bear metabolic side effects without clear oncologic gain. Identifying responsive subtypes allows clinicians to target intensive treatments to individuals with demonstrable survival benefits while protecting others from unnecessary metabolic strain.

Required Validation Steps Before Routine Clinical Application

The findings represent a retrospective analysis of trial tissue and require prospective validation before altering current clinical guidelines. The authors noted that future clinical trials must confirm whether the PAM50 classifier works reliably as a predictive biomarker across broader patient groups. Until prospective trials validate the tool, standard salvage therapy selections continue to follow established clinical staging and PSA kinetics.

Patients recovering from prostate surgery can discuss tumor characteristics and metabolic monitoring with their oncology team. Questions regarding whether genomic profiling is appropriate depend on individual risk category, surgical margins, and post-operative PSA trajectory. Patients initiating androgen suppression can also request metabolic baselines, including fasting glucose and lipid panels, to manage physical recovery during therapy.